{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:02:55Z","timestamp":1791302575446,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.ejso.2008.12.013","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T09:32:56Z","timestamp":1234344776000},"page":"515-520","source":"Crossref","is-referenced-by-count":135,"title":["Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX\/FOLFOX therapy of colorectal\u00a0cancer liver metastases"],"prefix":"10.1016","volume":"35","author":[{"given":"M.","family":"Klinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Eipeldauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Herberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tamandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dorfmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Koelblinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gruenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Gruenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2008.12.013_bib1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2008.12.013_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.1125950","article-title":"Antiangiogenic therapy: a universal chemosensitization strategy for cancer?","volume":"312","author":"Kerbel","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejso.2008.12.013_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2008.12.013_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdg731","article-title":"Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases","volume":"14","author":"Adam","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10353-006-0229-9","article-title":"Interdisciplinary management of colorectal cancer liver metastases","volume":"38","author":"Gruenberger Th","year":"2006","journal-title":"Eur Surg"},{"key":"10.1016\/j.ejso.2008.12.013_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2407-8-120","article-title":"Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases","volume":"8","author":"Gruenberger","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2008.12.013_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000193603.26265.c3","article-title":"Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases","volume":"243","author":"Karoui","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2008.12.013_bib8","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","article-title":"Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer","volume":"26","author":"Gruenberger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jamcollsurg.2005.09.010","article-title":"Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases","volume":"202","author":"Rubbia-Brandt","year":"2006","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejso.2008.12.013_bib10","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ejso.2008.01.001","article-title":"Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases","volume":"34","author":"Kandutsch","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib11","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.sla.0000193599.57858.9b","article-title":"CASH (Chemotherapy-Associated Steatohepatitis) costs","volume":"243","author":"Fong","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2008.12.013_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/annonc\/mdl386","article-title":"Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery","volume":"18","author":"Rubbia-Brandt","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejso.2008.12.013_bib15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bcp.2007.09.029","article-title":"Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis","volume":"75","author":"Selvakumaran","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejso.2008.12.013_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the\u00a0VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2008.12.013_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2008.12.013_bib18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of\u00a0a\u00a0histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2008.12.013_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2008.12.013_bib20","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","article-title":"Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases","volume":"24","author":"Aloia","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Nakano","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2008.12.013_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/bjs.5719","article-title":"Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases","volume":"94","author":"Zorzi","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2008.12.013_bib23","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cncr.23099","article-title":"Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases","volume":"110","author":"Ribero","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2008.12.013_bib24","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jhep.2005.08.018","article-title":"Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats","volume":"44","author":"Namisaki","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejso.2008.12.013_bib25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-07-4081","article-title":"Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels","volume":"14","author":"Brostjan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2008.12.013_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2006.08.002","article-title":"Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer","volume":"33","author":"Ellis","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib28","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","article-title":"Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST","volume":"22","author":"Ratain","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib29","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib30","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2008.12.013_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2007.13.8099","article-title":"Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798308018799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798308018799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T17:26:56Z","timestamp":1545413216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798308018799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0748798308018799"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2008.12.013","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}